Conference and Presentation Archive
A list of conferences, tutorials, executive briefings and such which I have previously organized, attended, and/or presented at. Interested in what I’ve been up to more recently? Here is my list of upcoming events.
|ICAAC 2011:ISAP Workshopsat the 51st ICAAC will be held on Friday, September 16, 2011 at the McCormick Place ChicagoISAP Workshops:51-01
Basics of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
Conveners: J. Mouton and H. Derendorf
William A. Craig, MD; Emeritus Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Hartmut Derendorf, PhD; Professor; Univ. of Florida, Gainesville, FL.
Alasdair MacGowan, MD; Professor; Bristol Ctr. for Antimicrobial Res., Bristol, United Kingdom.
Johan W. Mouton, PhD; Professor; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria51-02 Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-Infective Agents
Conveners: J. Mouton, U. Theuretzbacher
David R. Andes, MD; Associate Professor of Medicine; Univ. of Wisconsin, Madison, WI.
Paul G. Ambrose, PharmD; Director; Ordway Res. Inst., Latham, NY.
Johan W. Mouton, PhD; Professor; Radboud Univ. Nijmegen Med. Ctr., Nijmegen, Netherlands.
Ursula Theuretzbacher, PhD; Principal; Ctr. for Anti-Infective Agents, Vienna, Austria.
Paul M. Tulkens, MD; Professor; Univ. Louvain, Bruxelles, Belgium.
Markus Zeitlinger, MD; Professor; Med. Univ. Vienna, Vienna, Austria
Tuesday, September 20th, 2011, 2:00 – 6:00 pm
Scientific presentations by junior investigators
|May 2011||Official symposium at ECCMID 2011, May, 7-10, 2011, Milano, ItalyBridging the gap of innovation – what we all could do. Arranged with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG) and the ISC Working Group:Antimicrobials of the Future* Antibacterial pipelines – what to expect in the future (U. Theuretzbacher)
* Political processes for the global need for effective antibiotics – moving towards concerted action (O. Cars)
* New ways of using old and coming antibiotics (J. Mouton)
* Improving usage by guidelines – the European experience (P. Tulkens)
|April 2011||Presentation at the conference: Resistance is Futile: The Challenge of Antibacterial Drug Development – Integrating of Chemistry and Biology
April 12-13, 2011 in San Diego, CA
PK/PD in the Drug Development Process — Learning from MistakesThe preclinical and early clinical PK assessment as well as PD studies provide the input for in vitro and in vivo PK/PD models that evaluate exposure-effect relationships. Such PK/PD models are powerful tools for human dose selection, for determining susceptibility breakpoints as well as strategies to mitigate resistance development. Recent late stage clinical failures illustrate the importance of understanding the impact of PKs such as protein binding and concentrations at infection sites and incorporating them early into adequate PK/PD evaluations.
|November 2010||Organized and held CEFAIA’s Executive Briefing – Nov 14, 2010 in Munich, Germany
Challenges in the antibacterial market – Resistance demands action
|October 2010||Presentation at the 7th Annual Anti-Infectives Partnering & Deal-Making Summit, Oct 7-8, 2010 in Boston, MA
The Global Need for New Antibiotics – International Actions and Implications for Antibacterial Drug DevelopmentThe pandemic of multi-drug resistant pathogens and their continuing spread is beyond dispute. Driven by concern regarding this rapidly worsening global health crisis and the confounding lack of robust drug pipelines, several multinational campaigns have initiated broad discussion and put action plans in place. In an impressive show of international interest, the ECDC, EMEA, WHO, and the US government, as well as the IDSA and several other large non-profit organizations, are addressing the global problem by bringing attention and focus to the problematic and systemic paucity of new antibiotics to combat drug-resistant bacteria.
• What are the predictions for future resistance development trends?
• How would the action plans influence the antibacterial R&D business?
• What are the challenges and opportunities arising from international action plans?
|September 2010||Presentation at the conference ‘The Global Need for Effective Antibiotics-Moving towards Concerted Action‘ in Uppsala, Sweden.At a historic three day conference at Uppsala University, Sweden, 190 delegates representing 45 countries and many leading stake holders – civil society, academia, industry, governments, authorities, supranational organizations – agreed to turn a new page and move towards concerted action on antibiotic resistance.The conference builds on discussions held at the expert Swedish EU Presidency meeting “Innovative Incentives for Effective Antibacterials” in September 2009. The participants consist of 150-200 invited researchers, policy makers, funders, governmental officials, and representatives from international organisations (including WHO) and from the industry. The foremost target groups for the conference are the EU Commission, the EU-US Task force on Antimicrobial Resistance and the WHO.
|September 2010||ASM press conference at ICAAC 2010: press release
||September 2010||My activities during the ICAAC 2010in Boston, MA included:
|Presentation at the 2nd Anti-Infectives Summit
September 27 – 29, 2010, San Francisco, CAMulti-Drug Resistance As A Driver In The Development Of New DrugsThe development of drug resistance limits the effectiveness of many anti-infectives. The changing face of the disease, emergence of more resistant strains and changes in patterns of infection all add to the risks assumed by a pharmaceutical company investing in the development of an antiviral therapeutic. Managing risks is an important part of survival in heavily competitive spaces. Only the fit firms with compelling cases for drug effectiveness survive. Topics to be discussed include:* Major patterns of drug resistance
* Risks associated with multi-drug resistant pathogens
* Techniques used to maximize effectiveness of therapeutics against resistance
|June 2010||Presentation at the16th Symposium of the Immunocompromised Host Society, 27-30 June 2010, Budapest, HungaryAntimicrobial PK-PD Issues for Cancer Patients (Abstract)A comprehensive review of pharmacokinetic and pharmacodynamics considerations of antimicrobial agents given to the immunosuppressed cancer and transplant patients. A tale beyond drug-drug interaction and clearance.|
|May 2010||My activities during the ECCMID2010 in Vienna, Austria included:
|November 2009||Executive Briefing presented by the Center for Anti-Infective Agents (CEFAIA)The 3rd Antibacterial Market Executive Briefing on November 1st, 14:00 to 18:00, in Vienna, Austria.Challenges in the antibacterial market
Moving out of survival mode
|September 2009||On behalf of ISAP, I organized the Post-ICAAC Antiinfectives Symposium in San Francisco
|September 2009||Invited to participate in the Educational Workshop in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC), San Francisco 2009, USA Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents
|May 2009||Presented at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)16-19th May 2009, Helsinki, Finland Educational workshop:
Pharmacokinetics and pharmacodynamics of anti-infective agents.
|March 2009||Invited to present at the 6th Anti-Infectives Partnering & Deal-Making Summit
March 5-6, 2009, Boston, MADiagnostics Team Up with Narrow-Spectrum Antibiotics: Synergistic Business Opportunities and Evolving Trends.The development of narrow-spectrum or single pathogen–only antibiotics is increasingly seen as attractive niche market opportunities. Resistance challenges, antibiotic control programs in hospitals, escalating health care costs, long development time lines, regulatory environment challenges, and dry pipelines, power the trend to more targeted therapies. Driven by the principles of personalized medicine, the hospital point-of care rapid diagnostic market promises dramatic market expansion via improved and rapid tests that are reliable and easy to integrate into hospital routine. Diagnostic-therapeutic co-development and early partnerships will be important drivers for targeting the clinical trial population and accessing markets more rapidly and efficiently. This overview discusses
• Existing examples for diagnostic-therapeutic partnerships
• Strategies for the clinical development phase
• Regulatory opportunities and pitfalls
• Synergistic strategies for diagnostic and drug development companies in the market
|December 2008||Invited to present at the Re-emerging Infectious Diseases conference
11th -12th December 2008, London UK Cultural implications for antibacterial drug development and usage
• Differences in general perception of medicine and antibiotic usage in US vs EU
• Medical need – everywhere the same?
• Cultural implications regarding drug development and commercialization strategies in US vs EU
|September 2008||Invited to participate in the Educational Workshop in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC), Washington D.C. 2008, USA Preclinical Pharmacokinetics and Pharmacodynamics of Anti-infective Agents Clinical Relevance of Pharmacokinetics and Pharmacodynamics of Anti-infective Agents
|November 2008||Organized and presented an Executive Briefing on November 16th in Mannheim, Germany – Optimizing partnering strategies in the anti-infectives market
The comeback of the antibacterial business.
|October 2008||Invited to present at the2nd World Conference on Magic Bullets(Ehrlich II) in Nürnberg, Germany, October 3 – 5, 2008 Oral presentation:
Evaluating our performance: Tissue penetration paradigm shift
|May 2008||Presented at the 18th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID):
|January 2008||Invited to present at 11th International Symposium
“Current Topics in Infectious Diseases“
January 27 – February 1, 2008 Antibiotics: what’s new and what’s in the pipeline?
|October 2007||Invited to present at FDA in Washington DC, Division of Pharmaceutical Evaluation III, Oct 22nd, 2007 – The Influence of Tissue Distribution and Protein Binding on Resistance. Abstract
|October 2007||Invited to participate in the APUA 2nd world congressin Boston, Oct 29-30th, 2007Symposium “Future Strategies in Drug Development and Prescribing”Robert C. Moellering, MD, Beth Israel Deaconess Medical Center, Harvard Medical School — “New concepts of anti-infective therapy” — Tentative
• Ian Gould, PhD, MBChB, FRCPE, FRCPath , Consultant Microbiologist, Aberdeen Royal Infirmary, UK — “Unintended consequences of prescribing
• Dominique L. Monnet, PharmD, PhD, Statens Serum Institut, Denmark — “Encouraging development of new antibacterials while preserving the old”
• Ursula Theuretzbacher, PhD, Center for Anti-Infective Agents — “Antimicrobials in the future”
• Steven J. Projean, PhD, Biological Technologies, Wyeth Research — “How can we control antibiotic resistance when we don’t understand it?”
|April 2007||Invited to run the Executive Briefing following the smi-conference Superbugs & Superdrugs in London, 23rd to 24th April 2007. This Executive Briefing explored the biggest issues in antibacterial resistance looking in-depth at the current market and forward 10 years into the future. Attendees joined in examining resistance challenges and examining the current R&D pipeline. Report: Resisting the call for new antibacterials?
|January 2007||Invited to present at the 4th Anti-Infectives Partnering & Deal-Making Summit – Jan. 25-26, 2007, San Francisco, USA
|Invited to participate in the ISC working session: Reconciling the goals of antibiotic policy and drug development.
17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and 25th International Congress of Chemotherapy (ICC), Munich/Germany, 31 March – 3 April 2007
Symposium, jointly organised by the ISC Working Group on Future Antimicrobials and the ESCMID Study Group on Antibiotic PoliciesConveners: Jean Claude Pechère, Geneva, CH
Inge C. Gyssens, Rotterdam, NLTopics:
Antimicrobials in the future
New concepts of anti-infective therapy
Optimal strategies for use of new antimicrobials
Panel discussionFaculty: Ursula Theuretzbacher, Vienna, AT
Robert C. Moellering, Boston, US
Dominique L. Monnet, Copenhagen, DK
Michael M. Dudley, San Diego, US
William A. Craig, Madison, US
Ian Gould, Aberdeen, UK
|Invited to present at the 8th European Conference of Chemotherapy in Budapest, Oct 25-28, 2006Abstract
|June 2006||Invited to present at the Annual Conference on Antimicrobial Resistance – June 26-28, Bethesda, USA
|April 2006||Invited to participate in the Educational Workshop of ISAP (International Society of Anti-Infective Pharmacology) in cooperation with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Nice 2006, France
|January 2006||Invited to present at the 3rd Anti-Infectives Partnering & Deal-Making Summit– Jan. 26-27, San Diego, USA Abstract
|October 2005||ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy(ICAAC), Washington 2005, USAIntroduction to PK/PD
H. Derendorf, PhD
Department of Pharmaceutics, University of Florida, Gainsville, FL PK/PD indices
J. Mouton, MD, PhD
Canisius Wilhelmina Hospital, Nijmegen, The Netherlands Protein binding, tissue distribution
Center for Anti-Infective Agents, Vienna, Austria In vitro models
I. Odenholt, MD
Departement of Infectious Diseases, Malmö University Hospital, Malmö, Sweden Animal models
Division of Infectious Diseases, University of Wisconsin, Madison, WI In vitro resistance
Division of Infectious Diseases, University Hospital, Uppsala, Sweden
|October 2005||Invited to participate in the symposium Clinical Issues of PK/PD organized by the
European Congress of Chemotherapy and Infection (ECC), Florence, ItalyAbstract Clinical Issues of PK/PD
Chairmen: W.A. Craig (USA) – F. Scaglione (Italy)
Thursday, October 20th 2005, 14.30 – 16.00
• PK/PD in special populations (H. Derendorf, USA)
• Clinical implications of tissue concentrations (U. Theuretzbacher, Austria)
• Clinical implications and recommendations based on PK/PD relationships (J.W. Mouton, The Netherlands)
• Role of clinical pharmacologists in the PK/PD aera (G.L. Drusano)
|October 2004||ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington 2004, USA
|September 2004||World Conference on Dosing of Antiinfectives, Nürnberg, Germany
Program: Introduction to PK/PD (Derendorf)
PK/PD indices (Mouton)
Protein Binding/Tissue Distribution (Theuretzbacher)
In vitro models (Mouton)
Animal models (Craig)
In vitro resistance (Cars)
|April 2004||ISAP (International Society of Anti-Infective Pharmacology) Educational Workshop
in cooperation with the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Prag 2004, Check Republic